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Background: Nontuberculous mycobacteria (NTM) is a disease of increasing incidence, causing 
permanent airway damage leading to destructive pulmonary disease. Medicare claims-based codes have 
been used to identify NTM infection and to evaluate trends in diagnosis and disease outcomes. 
However, claims-based codes to identify NTM infection have not been validated.  
 
Methods: We linked patients with a bronchiectasis diagnosis (ICD-9-CM 494.0 or 494.1) excluding cystic 
fibrosis from the national 2006-2014 Centers for Medicare and Medicaid (Medicare) data to the U.S. 
Bronchiectasis Research Registry (BRR). The BRR is a national prospective cohort of patients with 
bronchiectasis, that collects detailed clinical, laboratory, microbiology and radiology data annually. We 
included BRR patients from 7 geographically varied sites, matched to Medicare data using social security 
numbers or deterministic matching by date of birth, and sex as well as associated physician up to 3 visit 
dates. Using one or more positive culture for any disease-causing NTM species in the BRR as the gold 
standard, we validated NTM claims codes (ICD-9-CM 031.0, 031.1, 031.2, 031.8 or 031.9) for 
identification of NTM infection. 
 
Results: Among 530 Medicare patients who are also in the BRR at the 7 sites, 459 (86.6%) were 
matched. Matched subjects had a mean age of 73.7 years (SD 6.2), were mostly female (82.4%), non-
Hispanic (98.1%) and white (96.8%). Using one or more claims +/- 6 and +/- 12 months of a positive BRR 
culture, claims codes had a sensitivity of 95.8% (95% CI: 91.8, 99.8) and 100% (95% CI: 96.2, 100) 
respectively. Using any positive BRR culture +/- 6 and +/- 12 months of a claim, culture had a PPV of 
96.3% (95% CI: 93.4, 99.2) and 100% (95% CI: 97.8, 100) respectively. 
 
Conclusion: To our knowledge, our study was the first to validate Medicare claims codes for pulmonary 
NTM in bronchiectasis patients. Our results indicate that claims may be used to identify NTM infection in 
the high-risk setting of bronchiectasis. 
